Evaluation of Specific Biomarkers in Primary Invasive Breast Cancer

GlaxoSmithKline (GSK)

Status: Terminated

Conditions: Neoplasms, Breast

Study type: Observational

Funder types: Industry

Identifiers

NCT01476111

115400

Details and patient eligibility

About

This study will examine specific biomarkers in primary invasive breast cancer and explore their correlation with patient outcome following standard neoadjuvant treatment.

Enrollment: 117 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• The patient has 18 years of age or older at the time of consent.
• The patient has provided pre-treatment tumor samples for WT1 expression screening and gene expression profiling in the context of the NCT01220128 study.
• The patient has a histologically or cytologically confirmed primary invasive breast cancer.
• The patient has provided written informed consent before any new information or new material is provided to the Sponsor.
• The patient is planned to receive, is receiving or has received standard and/or investigational therapy for breast cancer.
• The patient is planned to receive, is receiving or has received standard and/or investigational therapy for breast cancer.

Exclusion criteria

Not applicable.

Trial design

117 participants in 1 patient group

Group 1

Description:

Patients with primary invasive breast cancer